Discover
SXTP
60 Degrees Pharmaceuticals, Inc.
1.75
10 x 1.62
2 x 2.16
bid
ask
-
0.01
0.57%
6 @ 04:00 PM
1.73 -0.02 (1.14%)
| Ytd | -13.79% | |
| 1y | -81.54% |
1.66
day range
1.92
1.22
52 week range
10.77
| Open | 1.66 | Prev Close | 1.76 | Low | 1.66 | High | 1.92 | Mkt Cap | 4.65M |
| Vol | 173.32K | Avg Vol | 124.27K | EPS | -6.76 | P/E | N/A | Forward P/E | -0.65 |
| Beta | N/A | Short Ratio | 0.34 | Inst. Own | 1.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.55 | 200-d Avg | 3.20 | 1yr Est | 3.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.6 | -0.93 | -0.33 | -55.00% |
| 2024-08-14 | 2024-06 | -3.96 | -4.23 | -0.27 | -6.82% |
| 2024-08-14 | 2024-06 | -3.96 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -1.92 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -1.92 | 0.36 | 2.28 | 118.75% |
| 2024-04-01 | 2023-12 | -3.24 | -5.28 | -2.04 | -62.96% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-23 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-12-11 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-09-13 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-06-06 | HC Wainwright & Co. | Upgrade | Neutral |
Profile
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-15 | ALLEN CHARLES W | Director | 14.00K | Conversion of Exercise of derivative security |
| 2024-05-15 | DOW GEOFFREY S | Chief Executive Officer | 762.63K | Conversion of Exercise of derivative security |
| 2024-05-15 | FIELD PAUL | Director | 14.00K | Conversion of Exercise of derivative security |
| 2023-07-27 | KNIGHT THERAPEUTICS, INC. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-05-15 | MILLER TYRONE | Chief Financial Officer | 176.93K | Stock Award(Grant) |
| 2024-05-15 | TOOVEY STEPHEN | Director | 14.00K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Virtu Financial LLC | 12.68K | 14.71K | 0.55% |
| 2024-09-29 | Citadel Advisors Llc | 10.10K | 11.71K | 0.44% |
| 2024-09-29 | National Bank of Canada/FI | 4.00K | 4.64K | 0.17% |
| 2024-09-29 | UBS Group AG | 3.31K | 3.84K | 0.14% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 1.47K | 1.71K | 0.06% |
| 2024-09-29 | Safe Harbor Fiduciary, LLC | 1.38K | 1.59K | 0.06% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 3.88K | 4.49K | 0.17% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.14K | 2.48K | 0.09% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 588.00 | 682.00 | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 4 | 2026-01-20 |
| 1 : 5 | 2025-02-24 |
| 1 : 12 | 2024-08-12 |